HomeCompareMDAW vs JNJ

MDAW vs JNJ: Dividend Comparison 2026

MDAW yields 666666.67% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MDAW wins by $8.275235618773884e+34M in total portfolio value
10 years
MDAW
MDAW
● Live price
666666.67%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$8.275235618773884e+34M
Annual income
$82,727,945,429,218,320,000,000,000,000,000,000,000,000.00
Full MDAW calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — MDAW vs JNJ

📍 MDAW pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMDAWJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MDAW + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MDAW pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MDAW
Annual income on $10K today (after 15% tax)
$56,666,666.67/yr
After 10yr DRIP, annual income (after tax)
$70,318,753,614,835,575,000,000,000,000,000,000,000,000.00/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, MDAW beats the other by $70,318,753,614,835,575,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MDAW + JNJ for your $10,000?

MDAW: 50%JNJ: 50%
100% JNJ50/50100% MDAW
Portfolio after 10yr
$4.137617809386942e+34M
Annual income
$41,363,972,714,609,160,000,000,000,000,000,000,000,000.00/yr
Blended yield
99.97%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

MDAW
No analyst data
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MDAW buys
0
JNJ buys
0
No recent congressional trades found for MDAW or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMDAWJNJ
Forward yield666666.67%2.13%
Annual dividend / share$2.00$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28%
Portfolio after 10y$8.275235618773884e+34M$30.3K
Annual income after 10y$82,727,945,429,218,320,000,000,000,000,000,000,000,000.00$4,689.40
Total dividends collected$8.275075881065991e+34M$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: MDAW vs JNJ ($10,000, DRIP)

YearMDAW PortfolioMDAW Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$66,677,367$66,666,666.67$10,592$272.30+$66.67MMDAW
2$415,506,651,117$415,435,306,334.37$11,289$357.73+$415506.64MMDAW
3$2,419,908,598,386,268$2,419,464,006,269,573.00$12,123$472.89+$2419908598.37MMDAW
4$13,171,697,643,084,456,000$13,169,108,340,884,183,000.00$13,141$629.86+$13171697643084.44MMDAW
5$67,004,927,492,790,120,000,000$66,990,833,776,312,020,000,000.00$14,408$846.81+$67004927492790120.00MMDAW
6$318,562,277,003,514,840,000,000,000$318,490,581,731,097,560,000,000,000.00$16,021$1,151.60+$318562277003514871808.00MMDAW
7$1,415,484,168,853,553,000,000,000,000,000$1,415,143,307,217,159,200,000,000,000,000.00$18,122$1,588.22+$1.415484168853553e+24MMDAW
8$5,878,130,573,362,507,000,000,000,000,000,000$5,876,616,005,301,833,000,000,000,000,000,000.00$20,930$2,228.20+$5.878130573362507e+27MMDAW
9$22,813,793,009,840,743,000,000,000,000,000,000,000$22,807,503,410,127,248,000,000,000,000,000,000,000.00$24,792$3,191.91+$2.2813793009840744e+31MMDAW
10$82,752,356,187,738,840,000,000,000,000,000,000,000,000$82,727,945,429,218,320,000,000,000,000,000,000,000,000.00$30,274$4,689.40+$8.275235618773884e+34MMDAW

MDAW vs JNJ: Complete Analysis 2026

MDAWStock

Media Way Corp. provides Web site design, hosting, online marketing, platforms for third party advertising and e-commerce for music artists and for its own entertainment destination site - amuZnet.com. Media Way designs, owns, hosts and maintains an integrated network of distinct types of entertainment based Web sites. Additionally, it produces exclusive new media content for the Internet, in audio and video form, which it is syndicating to several large Tier-1 partners. Some of the material is also produced with the view, to repurpose it for interactive satellite broadcasting and other broadband channels. Media Way has signed contracts with EchoStar (Dish Network) for the launch of an Interactive Satellite Entertainment Channel. The company is based in Los Angeles, California.

Full MDAW Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this MDAW vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MDAW vs SCHDMDAW vs JEPIMDAW vs OMDAW vs KOMDAW vs MAINMDAW vs ABBVMDAW vs MRKMDAW vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.